TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Meningitis
Reports from Chang-Gung University highlight recent research in meningitis
December 2nd, 2008
According to recent research from Taiwan, "Meropenem (MEM; 2g/8hr; minimum inhibitory concentration [MIC] = 256 mg/L) plus sulbactam (SUL; 1g/8hr; MIC = 128 mg/L) (two-drug-therapy period), and subsequent additional intravenous colistin (COL; 2.5mg/kg/12hr) and intraventricular (COL, 5mg/day; MIC = 1 mg/L) (three-drug-therapy period) were sequentially used in a patient with postneurosurgery bacteremic meningitis due to a multidrug-resistant Acinetobacter baumannii (MDRAB) isolate (AB(1)). We detected 4- to 32-fold increases in peak or trough cerebrospinal fluid bactericidal titer and serum bactericidal titer in three-drug-therapy period when comparing to those in two-drug-therapy...
Source: TB & Outbreaks Week (2008-12-02)
|
